Novartis's pelacarsen fails to cut heart-attack risk in Lp(a) trial

GoKawiil's interpretation of the reporting above, not reported fact.

Lp(a) is a genetically determined risk factor that cannot be managed through diet, exercise or existing cholesterol drugs, so researchers had pinned hopes on this new class of therapies to close a major treatment gap. The unexpected failure raises doubts, according to cardiologist Michelle O'Donoghue, about whether lowering Lp(a) numbers alone is enough to improve patient outcomes, which could affect how other Lp(a)-targeting drugs still in late-stage trials are evaluated. Until the cause of the failure is understood, it remains unclear whether the entire therapeutic approach needs rethinking or whether pelacarsen specifically underperformed.

• Novartis's pelacarsen failed to reduce heart attacks, strokes and related events in a major trial despite cutting Lp(a) levels by over 80%.
• Lp(a) is largely genetically determined and has no approved lowering therapy, making the failure a setback for a widely anticipated drug class.
• The reason for the trial's failure is unknown, and Novartis has not commented, leaving the fate of other Lp(a)-lowering drugs in development uncertain.